MHRA Letter for Supply of Medicines for Medical Abortion During COVID-19 Pandemic

4 April 2020

One of the challenges in implementing early medical abortions (EMAs) has been the interpretation of the regulations of packing medicines into suitable quantities when these are not immediately available. The regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), has cleared guidance (see link below) with their own legal team and the Care Quality Commission (CQC) and it can be implemented with immediate effect. The MHRA still expect good medicine’s management, and so any drugs cut down and repacked must have clear instructions, and it must be clear for patients what to take and when. 

Hopefully this will give healthcare service teams and providers the reassurance and authority they need to give out the correct medication in appropriate quantities.

MHRA Letter for supply of medicines for medical abortion during COVID-19 pandemic signed

Dr Jonathan Lord (BSACP Co-Chair)